C-terminal modification of the insulin B:11–23 peptide creates superagonists in mouse and human type 1 diabetes

Yang Wang*, Tomasz Sosinowski#, Andrey Novikov*, Frances Crawford*, David B. Neau*, Junbao Yang*, William W. Kwok*, Philippa Marrack*, John W. Kappler*, and Shaodong Dai**

Abstract

A polymorphism at Jβ7 in some major histocompatibility complex class II (MHCII) alleles of rodents and humans is associated with a high risk for developing type 1 diabetes (T1D). However, a highly diabeticogenic insulin B chain epitope within the B3–23 peptide is presented poorly by these alleles to a variety of mouse and human CD4 T cells isolated from either nonobese diabetic (NOD) mice or humans with T1D. We have shown for both species that mutations at the C-terminal end of this epitope dramatically improve presentation to these T cells. Here we present the crystal structures of these mutated peptides bound to mouse IAg7 and human HLA-DQ8 that show how the mutations function to improve T-cell activation. In both peptide binding grooves, the mutation of B:22R to E in the peptide changes a highly unfavorable interaction to improve T-cell activation. Furthermore, a second mutation of the adjacent B:21 (E to G) removes a side chain from the surface of the complex that is highly unfavorable for a subset of NOD mouse CD4 cells, thereby greatly enhancing their response to the complex. These results point out the similarities between the mouse and human responses to this B chain epitope in T1D and suggest there may be common posttranslational modifications at the C terminus of the peptide in vivo to create the pathogenic epitopes in both species. A

autoimmunity | peptide presentation | self-tolerance | posttranslational modification

The risk of developing type 1 diabetes (T1D) is closely linked to polymorphisms in major histocompatibility complex class II (MHCII) genes (1–4). For example, in humans, the highest risk T1D genetic risk factor is a single polymorphism in the β chain of HLA-DQ (DQ) within the codon for Jβ7 that lies within the peptide binding groove (5–7). Low-risk DQ alleles and most other MHCII alleles in humans and rodents have a D at this position. Substitutions for this D in the high-risk alleles break a preference for a p9 acidic amino acid. However, despite decades of experimentation, the reasons for this association are still debated.

We have studied a peptide from the insulin B chain, B:9–23 (SHLVEALYLVCGERG), shown to contain an essential epitope(s) for CD4 T cells in the development of spontaneous T1D in the NOD mouse model (11). Many CD4 insulin-recognizing T cell clones from the islets of prediabetic NOD mice target the insulin B:9–23 peptide (12, 13), and CD4 T cells targeting this peptide have been identified in humans as well (14, 15). This peptide can potentially occupy various positions or registers (Rs) in the binding groove of IAβ7, the only MHCII molecule in NOD mice (Fig. 1A). For example, R1 places VEALYLVCGER in the p1–p9 positions of the groove and R2 places EALYLVCGER in p1–p9. While the binding of this peptide in R1 and R2 has been demonstrated by ourselves and others (13, 16), our data accumulated over the past 8 y have shown that neither of these Rs creates the diabeticogenic MHCII–peptide complex for a wide variety of NOD CD4 T-cell clones, which we conclude recognize the peptide in R3, which would place ALYLVCGER in p1–p9 (16–18). This was a highly unexpected result, since in this register the R at the p9 position of this peptide greatly interferes with binding to IAβ7. We showed that mutation of p9R to an optimal E dramatically improved binding to IAβ7 in R3 by about 100-fold (16). While this increase in binding was sufficient for a strong increase in activation of about half of B:9–23-specific NOD T-cell clones, we showed that a second mutation, p9E to G, was required as well to get strong activation of the other half (17).

Significance

Insulin is a target of CD4 T cells in type 1 diabetes in mice and humans. Why the major epitope in the insulin B chain is presented poorly to the diabeticogenic CD4 T cells by the disease-associated major histocompatibility class II (MHCII) alleles has been highly debated. Here we present high-resolution mouse and human MHCII structures and T-cell functional data to show that C-terminal modifications of this epitope are required for binding and presentation in the appropriate position in the MHCII binding groove. These results suggest that pancreas-specific posttranslational modifications of this peptide may play a role in the induction of diabetes and explain how the pathogenic T cells escape deletion in the thymus.

Author contributions: Y.W., J.W.K., and S.D. designed research; Y.W., T.S., A.N., F.C., D.B.N., J.W.K., and S.D. performed research; T.S., J.Y., and W.W.K. contributed new reagents/analytic tools; Y.W., T.S., F.C., D.B.N., P.M., J.W.K., and S.D. analyzed data; and Y.W., P.M., J.W.K., and S.D. wrote the paper.

Reviewers: M.P., Baylor College of Medicine; and L.I.S., University of Massachusetts Medical School.

The authors declare no conflict of interest.

This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

Data deposition: The atomic coordinates and structure factors have been deposited in the Protein Data Bank, www.rcsb.org [PDB ID codes (IAg7p8E9E) 6BLQ, (IAg7p8E96)R 6BLR, (IAg7p8E96)6 6BLX, and (IDQ8p8611s)5UJT].

1To whom correspondence may be addressed. Email: kappler@njihealth.org or dais@njihealth.org.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1716527115/-/DCSupplemental.
The two populations defined with these mutated peptides correlated, respectively, with the type A and type B insulin-reactive CD4 T cells, previously described by U mean and coworkers (13, 19), which they proposed recognized the peptide bound in R2 and R1, respectively. We went on to show that type A T cells were also present in human patients with T1D, revealed by the dramatically improved T-cell response to the B:22R to E mutated peptide bound to HLA-DQ8 (DQ8) (14, 15).

Thus, rather than promoting the presentation of the diabetic insulin epitope, the MHCII β7 polymorphisms in fact inhibited the presentation of the natural peptide in the proper R. We have proposed that pancreatic posttranslational modifications of this epitope at p9 and sometimes at p8 as well may be required for effective presentation in vivo and could explain how diabetogenic CD4 T cells escape thymic negative selection and find their neoantigen targets in the pancreas (18, 20). Here we support these ideas with crystallographic structures of the mutated peptides bound to mouse IAβ7 and human DQ8. The structures confirm the R3 binding nature of the different versions of the functional MHCII/insulin complexes from both mice and humans. They also elucidate the key feature of p8 in discriminating type A and type B specificities of the T cells in the NOD mouse model. We hypothesize that pancreatic-specific modifications of the C terminus of the B:9–23 peptide in vivo may be needed to create the functional epitopes for CD4 effectors in T1D.

Results

C-Terminal Modifications of an Insulin B Chain Peptide Create IAβ7 R3-Bound Superagonists for both Type A and B CD4+ Insulin-Reactive T Cells from NOD Mice. Our previously published data showed that type A and type B insulin-reactive mouse T cells recognize the B chain 9–23 peptide bound with R3 anchor residues. Both types of T cells required a mutation of the natural R at p9 to E for strong IAβ7 binding. In addition, the type A T cells strongly preferred the surface-exposed natural p8E, but the type B T cells preferred the additional p8E to G mutation (14–17). As shown in Fig. 1, to study this phenomenon, we have prepared a variety of insulin peptides modified in this way either as soluble peptides (Fig. 1B) or as peptides tethered in multiple ways to IAβ7 or DQ8 (Fig. 1C). We have studied the activity of these peptides with a variety of human and mouse insulin-reactive CD4 T-cell hybridomas or T-cell receptor (TCR)-transduced T-cell avatars whose origins and properties are described in Materials and Methods and Table S1. To demonstrate the dramatic effects of the 8E9E and 8G9E peptide modifications, we compared their stimulatory activities to that of the wild-type WT8E9R peptide using IL-2 secretion assays with fixed M12.C3-IAβ7 B lymphoma cells as antigen-presenting cells (APCs) and eight (four type A and four type B) NOD mouse CD4 T cells as responders (Fig. 2). We used an IAβ7 binding peptide from hen egg lysozyme (HEL) as a negative control (21).

Fig. 2. Mutations to the B:12–22 peptide create reciprocal superagonists for type A vs. type B insulin-reactive T cells. (A) Various concentrations of soluble WT8E9R (black), 8E9E (red), and 8G9E (blue) peptides (Fig. 1B) were presented by fixed M12.C3-IAβ7 cells to two NOD mouse type A and two type B insulin-reactive T cells (Table S1). Results of a single experiment are presented as IL-2 produced after 24 h vs. the concentration of the offered peptide. The HEL peptide was used as a negative control (green). (B) Peptide titration experiments were performed as in A with all eight NOD mouse T cells listed in Table S1. The titration data were fitted with parallel third-order polynomial curves. The peptide potency was defined as the shift in the titration curve relative to that of the WT8E9R peptide. Results are shown as the geometric average and SEM of three separate experiments.

Wang et al. PNAS | January 2, 2018 | vol. 115 | no. 1 | 163
type A (I.29 and PCR-1.10) and two type B (8F10 and 8–1.1) T cells as described in Materials and Methods. We also prepared soluble versions of IAβ tethered to versions of the 8E9E or 8G9E peptide (Fig. 1C) via a flexible linker attached to the IAβ β chain N terminus (16, 17). These contained the natural C at p6, but the p1A was mutated to R to further assure stable binding to IAβ in R3 (21). Also, a second version of the IAβ–8E9E complex was made using IAβ, whose o62N was mutated to C (8E9E6ss), thus allowing a disulfide to form between the peptide p6C and the mutated IAβ o62C (16, 17). This version was used with the I.29 TCR, since we had shown in a previous study (17) that the fluorescent IAβ–8E9E6ss tetramer bound I.29 better than the 8E9E tetramer. In these experiments, IAβ bound to the HEL peptide was used as a negative control. These soluble IAβ constructs were also stabilized with an acid-base leucine zipper and contained a biotinylated peptide tag (17).

The biotinylated IAβ complexes were captured in separate flow cells of a BIAcore streptavidin (SA) BIAsensor chip. The various concentrations of soluble type A (Fig. 3A) or type B (Fig. 3B) TCRs were injected through the flow cells while following the binding and dissociation from the IAβ complexes via the SPR signals after correction for the fluid phase signal from the flow cell with the control IAβ–HEL complex. As with the stimulation assays in Fig. 2, reciprocal specificities were observed in these TCR binding assays. The type A I.29 TCR binding was very similar to the first-order kinetics to the IAβ–8E9E6ss ligand, as did the PCR1–10 TCR to IAβ–8E9E, with dissociation constants of 13.9 and 5.1 μM, respectively. The I.29 TCR also bound to the IAβ–8E9E complex that lacked the disulfide but, as expected, with poorer affinity (~100 μM). These type A TCRs bound very poorly or not at all to the 8G9E complex. The 8–1.1 and 8F10 type B TCRs failed to bind to the 8E9E complex, but both bound strongly to the 8G9E complex. The 8–1.1 TCR bound with first-order kinetics with a dissociation constant of 3.5 μM. The 8F10 TCR showed second-order kinetics, consistent with a two-state reaction, in which the TCR initially bound with rapid kinetics but then bound more strongly after a conformational change, leading to an overall apparent dissociation constant of ~10 μM. These affinities are typical for conventional CD4 T cells with high affinity for conventional self–MHCII–foreign peptide complexes.

High-Resolution Crystal Structures Show How the Peptide Mutations Determine Presentation by IAβ. Both the T-cell stimulation and SPR experiments above show the superagonist properties of the C-terminally modified peptides. These results are consistent with our previous interpretation of mutational data, concluding that the B22R to E mutation creates an optimal R3 p9 anchor amino acid that can overcome the B22R inability to fill the IAβ p9 pocket and that the adjacent B21E to G mutation removes the R3 p8E side chain that is inhibitory for type B TCRs. However, to offer unequivocal structural evidence for this interpretation, we crystallized the 8E9E, 8E9E6ss, and 8G9E complexes with IAβ after proteolytic removal of the zippers and biotinylation tag from the proteins and solved their structures at 1.8 Å, 2.0 Å, and 2.3 Å, respectively (Fig. 4 and Table S2).

Electron density maps clearly show unambiguous density for the peptides in the three structures (Fig. 4A and Fig. S1). As predicted, all three peptides sit in R3 in the IAβ binding groove, with peptide anchor amino acid side chains from p1R, p4L, p6C, and p9E pointing into the corresponding IAβ pockets within the binding groove. The mutated p1A A > R and p9 R > E side chains (Fig. 4B) optimally fill the p1 and p9 pockets, forming numerous salt bridges, H bonds, and van der Waals interactions with IAβ amino acids lining the pockets, confirming our rationale for using these mutations to stabilize R3 binding. As expected, none of the side chains of the anchor residues are exposed on the surface of the complexes, but in all three structures, the side chains of the p-2V, p-1E, p2L, p3Y, and p5V amino acids are similarly positioned on the surface and accessible for potential TCR interaction (Fig. 4C). Most importantly, in the 8E9E and 8E9E6ss structures, the side chain of p8E is well-exposed on the surface, pointing straight up out of the groove, while in the 8G9E structure, the absence of a side chain at the p8 position leaves a stretch of the peptide from p6 to p10 with only the backbone of the peptide exposed on the surface. Surface electrostatic analysis shows that the 8E9E, 8E9E6ss, and 8G9E structures have similar surface potentials around the N-terminal part of the peptide, but the 8G9E structure differs conspicuously from the other two around the p8 position (Fig. S2). Therefore, both exposed surface and charge differences around the p8 position support our previous conclusion that the p8 amino acid is the deciding surface feature in discriminating type A and type B specificities of the T cells.

Comparison of the IAβ–8E9E and IAβ–8E9E6ss structures may also explain why introducing a disulfide between p6C and the o62C in the IAβ–8E9E6ss complex improves I.29 TCR binding and I.29 T-cell activation. For the most part, the TCR-facing surfaces of the 8E9E and 8E9E6ss complexes are very similar (Fig. 4C). However, as shown in Fig. S3, the disulfide introduced between p6C and o62C causes movement of the critical p3Y side chain toward the p5V, bringing the OH of p3Y ~1.5 Å closer to IAβ αQ61, which now bridges the OH of p3Y and the backbone O of p6C via 2 H bonds. We suggest that optimal preorienting of these amino acids for I.29 TCR interaction could account for the increased I.29 TCR affinity for the 8E9E6ss complex.

Human DQ8 and Mouse IAβ Present the Mutated Insulin Peptide Very Similarly. Proinsulin is an important autoantigen in both human T1D and the NOD mouse T1D model. As in mice, a polymorphism in human DQ8 β57 also breaks a salt bridge to α76R, creating a p9 pocket that greatly prefers D or E side chains and rejects K and R (9, 10). Two previous studies have shown that, like the type A mouse insulin-reactive CD4 T cells characterized above, human T1D patients contain CD4 T cells that strongly
recognize versions of the B:11–23 peptide (identical between mice and humans) presented by DQ8 only when B22R is mutated to E (14, 15). We have converted three T-cell clones isolated in one of these studies (14), T1D3, T1D4, and T1D10 (Table S1), to TCR-transduced T-cell avatars. We compared the response of the avatars to the soluble 8E9E vs. WT8E9R peptide presented by a DQ8 APC (Fig. 5A). As with the original T-cell clones, all three avatars responded much more strongly to the 8E9E, than to the WT8E9R, peptide, with the 9R to E mutation presented as IL-2 produced after 24 h vs. the concentration of the offered peptide. Similar results were obtained in a second experiment. (B) A biotinylated soluble version of the DQ8–8E9E11ss was immobilized in culture wells coated with Extravidin (Sigma). The same three insulin-reactive human T cells were added and IL-2 production assayed at 24 h. A mouse T cell (PCR1–10), highly reactive to the same peptide bound to IAβ7, was used as the negative control. (C) 2Fe–Fc electron density maps contoured at 1σ within 1.5 Å of the IAβ7, 8E9E6ss, and 8G9E peptides bound to IAβ7 are shown with the amino acid at each position in the MHCII binding groove labeled. The mutated amino acids are labeled in red. (D) Water-accessible surfaces of the IAβ7–8E9E are shown with oxygen, red and nitrogen, blue. Carbons are colored as follows: peptide, white; α chain, cyan; β chain, magenta. The side chains of p1R and p9E from the other two structures are shown superimposed, 8E9E6ss (carbons, yellow) and 8G9E (carbons, green). H bonds and salt bridges are shown with green lines. (E) Water-accessible surfaces of the IAβ7 complexes are shown (α chain, cyan; β chain, magenta; peptide backbone, yellow; peptide exposed side chains, red; peptide buried side chains, blue). Exposed amino acids p-2, p-1, p2, p3, p5, and p8 are labeled.

**Discussion**

The data that we present here and previously (14–17) argue convincingly that in both mouse and humans, most CD4 T cells reactive to the B9–23 insulin peptide recognize it bound to IAβ7 or DQ8 in R3. The question of R might seem to some a minor issue, but we point out that each shift in R of a peptide in an MHCII binding groove brings an entirely new set of amino acids to the surface. The resulting MHCII–peptide complexes are as different from each other as they are from the same MHCII bound to peptides from other foreign or self-proteins. The structures that we present here indicate that, from the point of view of the responding T cell, when bound to IAβ7 in R3, all of the complexes form very similar TCR interaction surfaces that differ from each other primarily at the exposed p8 position. Also, we show that the contribution of the mutated peptide to the surface of DQ8 is virtually identical. Concluding that the epitopes all bind in the same R in IAβ7 and DQ8 helps clear the confusion over the conflicting data about this peptide, emphasizes the similarity in how humans and mice recognize this peptide
in T1D, and makes possible the design of antigen-specific diagnostic and therapeutic reagents.

Why particular MHCII alleles are strongly associated with risk for various autoimmune diseases in humans and mice has remained a puzzle for several decades. The initial prediction was that certain epitopes from proteins targeted in these diseases would be selected based on their ability to bind to these MHCII alleles. However, more recent data have suggested a very different explanation for the MHCII linkage. One example is in rheumatoid arthritis, where peptidylarginine deiminase conversion of arginine to citrulline in some epitopes from synovial proteins greatly improves their presentation by HLA-DR4 to some pathogenic CD4 T cells (23). Another example is in Celiac disease, where conversion of glutamine to glutamic acid by transglutaminase greatly improves presentation of a number of gliadin epitopes by HLA-DQ2 and -DQ8 to CD4 T cells (24). Since these modifications occur in the target tissue, these results offer a reasonable explanation for how the relevant pathogenic T cells escape negative selection in the thymus but eventually find their targets in the tissue to initiate disease in individuals with the appropriate MHCII alleles. Thus, the high-risk MHCII alleles are unable to present the epitopes in the thymus but effectively present the modified epitope in the target organs.

Our results suggest that a parallel mechanism may be at play in T1D in the CD4 T-cell response to the insulin B9–23 peptide in mice and humans. The relevant wild-type epitope within this peptide is poorly presented in the relevant R (R3). Our finding that mutations at p8–B21E and/or p9–B22R solve this problem raises the question of how these substitutions might occur in vivo in the pancreas. There is no simple enzymatic way to achieve these transitions in situ in the protein. However, we have proposed a solution (20) based on recent evidence showing that a natural proteolytic process, transpeptidation, can carry out these kinds of modifications (reviewed in refs. 25 and 26). Transpeptidation is a form of reverse proteolysis in which the transient covalent bond that is formed between the active-site serine, threonine, or cysteine of proteases and the new carboxylate at a cleavage site, instead of being broken by water to complete the cleavage reaction, is attacked by the N terminus of a nearby peptide to reestablish a peptide bond, thus creating a hybrid peptide. Transpeptidation, first studied in the 1930s, surfaced as a mechanism for generating T-cell epitopes in the 2000s in a series of papers showing how this protease-driven mechanism in the proteasome could account for the creation of MHC-I-presented neoantigens in cancer (27, 28). Most recently, Liepe et al. (29) have provided evidence that naturally processed peptides eluted from the human MHC-I allele, HLA-A2, contain a very high proportion of chimeric peptides formed in the proteasome by the fusion between fragments from the same or different self-proteins.

We have proposed transpeptidation as a means of creating superagonists in T1D for CD4 T cells specific for insulin and other proteins (20), and recently several examples of fused peptide agonists have been identified in a mouse primary insulinoma tumor for T cells specific for chromogranin A and islet amyloid polypeptide (30). An examination of the sequences of mouse and human proinsulin reveals many potential donors within C peptide that could be fused by internal transpeptidation deletion to an insulin B chain acceptor cleaved at B:20 or B:21 to generate peptides similar or identical to the mutated peptides used in our experiments. The transpeptidation reaction is favored in situations where proteins are digested by the appropriate proteases in a confined space with limited water and a high local concentration of the donor peptide, often achieved by donors that are within the same protein as the acceptor. In the case of MHC-I epitopes, these conditions are achieved within the proteasome. In the case of MHCII, the lysosome may be a more likely site for the reaction, either in the beta cell itself or in islet-resident APCs (B cells, dendritic cells, etc.). Within the beta cell, two stress-related events could trigger the process within proinsulin. The first is crinophagy, where the level of beta cell secretory granules is regulated by fusion to lysosomes during normal and stress-induced catabolism of granules (31). The second is autophagy, where ER stress leads to enhanced misfolding of proinsulin, which is eliminated from the ER in vesicles that are destroyed in part by fusion with lysosomes (32).

Materials and Methods

T-Cell Hybridomas and T-Cell Transfectomas. For APCs, we used two versions of the M12.C3 B-cell lymphoma, one expressing IAα7 (M12.C3.g7) (33) and the other expressing DQ8 (M12.C3-DQ8-B) (34). The 12–4.1, 12–4.4, PCR1–10, and –8–1.1 hybridomas or avatar transductomas were produced at the Barbara Davis Center (11, 35, 36). The 12–4.1 T cell was transduced with high-affinity mutant human CD4 (37) to improve its antigen sensitivity. The A5150 and A591 T-cell hybridomas were obtained from Emil Unanue at Washington University, St. Louis. The original I.29 T-cell hybridoma was obtained from Matteo Levissetti, Washington University, St. Louis. In this paper, to avoid confusion, we are using with the original type A vs. type B nomenclature for the T cells instead of our original type II vs. type I nomenclature. E. Unanue also provided us with the CDR3 sequences of the BP10 TCR, which we used to construct a SKC-human TCR(Aβ)-transducet avatar. The N18T and TI10 human T-cell clones were produced at the Benaroya Institute (14). We cloned the TCR genes from these T cells and constructed SKC-transduced T-cell avatars as above, coexpressing unmutated human CD4. All cells were cultured in enriched MEM containing 10% FCS as previously described (38).

Antigen Presentation Assays and Soluble Peptides. T-cell hybridomas or TCR-transduced avatars (103 cells) were mixed with 106 paraformaldehyde-fixed (17) M12.C3.g7 or M12.C3.DQ8-B APCs and cultured overnight with various concentrations of peptide in a volume of 250 µL. Secreted IL-2 was assayed with either a functional assay, following the growth and survival of the HT-2 IL-2–dependent cell line (38), or with an ELISA-based assay for IL-2 (39). For presentation of soluble DQ8-p89E11ls, a biotin-tagged version (22) was captured in Extravidin (Sigma-Aldrich)-coated culture wells. Hybridomas or avatars were transfected with IL-2 producer plasmids used as above. The potencies of mutant peptides compared with the WT8E9R peptide were calculated by fitting a set of parallel third-order polynomial curves to the titration data and determining the shift of the mutant and chimeric peptide data on the log10 x axis relative to the WT8E9R data, which were assigned a potency value of 1. All soluble versions of insulin B chain containing peptides had the natural C at B:19 (p6) changed to A to avoid peptide dimerization in solution. This mutation had been previously shown to have no detrimental effect on peptide binding to IAα7 or T-cell activation (16). Soluble peptides (>95% pure) were obtained from either CHI Scientific or Schafer-N.

Protein Expression and Purification. As previously described (17, 20), acid-base leucine zipper stabilized, soluble IAα7 and human HLA-DQ8 molecules with covalently attached peptides were produced in baculovirus-infected insect cells and purified by chromatography. A biotinylated peptide tag was attached to the C terminus of the acidic half of the zipper, which was enzymatically biotinylated with BirA, produced in our own laboratory, after purification of the molecule. For crystallization, the zippers and biotinylation tag were removed with papain.

Two expression systems were used for producing soluble TCRs for biophysical studies. Soluble I.29, PCR1–10, and PCR8–1.1 TCRs were produced in baculovirus-infected insect cells as previously described (40), and the V domains of BF10 were expressed in a bacterial vector to produce a soluble scFv tagged with 6His (41, 42), which was purified from the transformed bacteria periplasm using immobilized Ni2+ chromatography.

Surface Plasma Resonance Measurements. Approximately 2,000 RU (resonance units) of biotinylated IAα7 bound to the B3E8, B9E6s6s, BC9E, or HEL peptides were captured in flow cells of a BIACore streptavidin BIAsensor chip. Various concentrations of soluble refolded TCRs were injected and the association and dissociation kinetics recorded and then corrected for the fluid phase SPR signal using the data from the IAα7–HEL flow cell as baseline. Kinetics was analyzed with BIACore BIAEval 4 software.

Protein Crystallization and X-Ray Data Collection, Data Processing, and Structural Analysis. The MHCII complexes were crystallized using the hanging-drop vapor-diffusion method. X-ray diffraction data were collected at the Advanced Photon Source, Argonne National Laboratory. Details are contained within SI Methods and Table S2.
1. Aly TA, et al. (2005) Genetic prediction of autoimmunity: Initial oligogenic prediction of anti-islet autoimmunity amongst DR3/DR4-DQB relatives of patients with type 1 diabetes. J Autoimmun 25(3):40-45.

2. Stadinski B, Kappler J, Eisenbarth GS (2010) Molecular targeting of islet autoantigens. Immunity 32:446-456.

3. Mordes JP, Bortolus M, Blankenhorn EP, Rossini AA, Greiner DL (2004) Rat models of type 1 diabetes: Genetics, environment, and autoimmunity. ILAR J 45:278-291.

4. Concannon P, Rich SS, Nepom GT (2009) Genetics of type 1A diabetes. N Engl J Med 360:1646-1654.

5. Xu H, et al. (2015) Additive and interaction effects at three amino acid positions in HLA-DQ and HLA-DR molecules drive type 1 diabetes risk. Nat Genet 47:898-905.

6. Morel PA, Dorman JS, Todd JA, McDevitt HO, Trucco M (1988) Aspartic acid at position 57 of the HLA-DQ beta chain protects against type I diabetes: A family study. Proc Natl Acad Sci USA 85:8111-8115.

7. Quartey-Papafio R, et al. (1995) Aspartate at position 57 of nonobese diabetic I-Ag7 beta-chain diminishes the spontaneous incidence of insulin-dependent diabetes mellitus. J Immunol 154:5567-5575.

8. Cooper AS, et al. (2000) A structural framework for deciphering the link between I-Ag7 and autoimmune diabetes. Science 288:505-511.

9. Lee KH, Wucherpfennig KW, Willey DC (2001) Structure of a human insulin peptide: HLA-DQ complex and susceptibility to type 1 diabetes. Nat Immunol 2:501-507.

10. Suri A, Walters JJ, Gross ML, Unanue ER (2005) Natural peptides selected by diabetogenic DQ8 and murine I-Ag7 molecules show common sequence specificity. J Clin Invest 115:2268-2276.

11. Nakayama M, et al. (2012) Germline TRAV5D-4 T-cell receptor sequence targets a primary insulin peptide of NOD mice. Diabetes 61:857-865.

12. Wegmann DR, Gill RG, Nordbury-Blaser M, Schloot N, Daniel D (1994) Analysis of the T-cell receptor of insulin-reactive CD4+ T cells. Science 264:148-151.

13. Nakayama M, et al. (2015) Regulatory vs. inflammatory cytokine T-cell responses to nonobese diabetic mice recognize a weak MHC-binding segment in more than one form. J Immunol 197:6051-6057.

14. Yang J, et al. (2014) Autoimmune T cells specific for insulin B11-23 recognize a low-affinity peptide register in human subjects with autoimmune diabetes. Proc Natl Acad Sci USA 111:14840-14845.

15. Nakayama M, et al. (2015) Regulatory vs. inflammatory cytokine T-cell responses to mutated insulin peptides in healthy and type 1 diabetic subjects. Proc Natl Acad Sci USA 112:4429-4434.

16. Stadinski BD, et al. (2010) Diabetogenic T cells recognize insulin bound to I-Ag7 in an unexpected, weakly binding register. Proc Natl Acad Sci USA 107:10978-10983.

17. Crawford F, et al. (2011) Specificity and interaction of insulin-reactive CD4+ T cells in type 1 diabetes in the nonobese diabetic (NOD) mouse. Proc Natl Acad Sci USA 108:16729-16734.

18. Marrack P, Kappler JW (2012) Do MHCIi-presented neoantigens drive type 1 diabetes and other autoimmune diseases? Cold Spring Harb Perspect Med 2:a007765.

19. Mohan JF, Petzold SJ, Unanue ER (2011) Regulator expression of an insulin peptide-MHC complex allows diabetogenic T cells to escape thymic deletion. J Exp Med 208:2273-2285.

20. Jin N, et al. (2015) N-terminal additions to the WE14 peptide of chromogranin A create strong autoantigenic agonists in type 1 diabetes. Proc Natl Acad Sci USA 112:13318-13323.

21. Lutsko RR, et al. (2000) Structural basis of peptide binding and presentation by the type I diabetes-associated MHC class II molecule of NOD mice. Immunity 12:699-710.

We acknowledge the contribution of Dr. Brian Stadinski during the early stages of this project. This work was supported by NIH Grants 5T32-Al-074491 (to Y.W.), ES-025797 (to S.D.), AI-18785 (to P.M.), DK-032083 (to T.S.), and AI-118688 (to J.W.K.), as well as JDRF Grant 1-PNF-2015-126-A-R, University of Colorado CCTSI Grant KL2 TR001080, and a Boettcher Foundation Investigator award (to S.D.). The synchrotron data were collected at Advanced Photon Source Argonne National Laboratory, Beamline 24 ID-C, whose work is based upon research conducted at the Northeastern Collaborative Access Team beamlines, which are funded by the National Institute of General Medical Sciences from National Institutes of Health Grant P41 GM103403. The Pilatus 6M detector on 24-ID-C beamline is funded by NIH-ORIP HEI Grant S10 RR025797.